Alzheimer’s Disease/Dementia News

LAS VEGAS — To slow or stave off symptoms relating to Alzheimer’s disease and dementia, individuals should make healthy habits a priority early in life, according to a presenter at BRAINWeek 2022.

Pharmaceutical companies Biogen and Eisai announced results from a phase 3 trial that demonstrated treatment with lecanemab reduced cognitive decline by 27% after 18 months compared with placebo.

Multimorbidity was associated with a 63% increased risk for incident dementia, with the greatest risk linked to hypertension and diabetes, researchers reported in JAMA Network Open.

Although it was well tolerated, the anti-amyloid antibody crenezumab did not reduce clinical decline in patients with Alzheimer's disease, researchers reported in JAMA Neurology.

Patients who experience delirium after a kidney transplantation are at an increased risk for dementia and cognitive decline, according to data published in the American Journal of Transplantation.

Maintaining a balanced energy intake through diet was associated with significantly better cognitive function compared with uneven intake patterns, researchers reported in Life Metabolism.

Alzheon Inc. reported statistically significant and clinically relevant results in patients with Alzheimer’s disease following 12 months of treatment with the oral investigational therapeutic ALZ-801 in its phase 2 trial.

Six metabolites — four related to sugar — were consistently associated with lower global cognitive function, researchers reported in Alzheimer’s & Dementia.

Cedars-Sinai’s department of computational biomedicine has been awarded an $8 million NIH grant to use artificial intelligence methods to identify genetic predictors of Alzheimer's disease.

The daily use of multivitamin-mineral supplements improved global cognition, episodic memory and executive function in older adults, researchers reported in Alzheimer’s & Dementia: The Journal of The Alzheimer’s Association.